Predix Pharmaceuticals, a drug discovery and development company, announced today that PRX-03140, its highly selective, proprietary serotonin 4 (5-HT4) receptor agonist, showed the desired alterations in brain wave activity in patients with mild-to-moderate Alzheimer’s disease and was well-tolerated in a recently completed 14-day Phase Ib clinical trial.
